The Ministry of Health has announced stricter controls on the sale and use of misoprostol, a widely used medication for reproductive health, with critics warning the move could drive demand underground.
In a press release dated April 3, the Ministry stated it was acting to curb what it described as the “widespread, unregulated sale and usage” of the drug across Liberia. Under the new regulations established by the Ministry, the World Health Organization (WHO)-recommended medical abortion pill will be dispensed only with a valid prescription and under the supervision of licensed pharmacists in approved facilities.
However, the government did not cite specific cases of misuse or abuse to support its claims, stating only that it had “noted, with alarm” the current situation. While the Ministry of Health frames the measures as necessary to protect public health, critics argue the decision will limit access to reproductive health services and infringe upon women’s bodily autonomy.
“When access to this drug is restricted, the ripple effects are felt by individuals, households, and communities,” Naomi Solanke, Community Health Initiative (CHI) executive director, said on a Facebook post as a reaction to the ministry’s statement.
Keep up with the latest headlines on WhatsApp | LinkedIn
Liberia currently maintains firm restrictions on abortion. The procedure is illegal except in cases of rape, incest, fetal abnormality, or risk to the woman’s physical or mental health. Even in these instances, two physicians must certify the medical exception, and evidence of rape or incest must be provided to the health minister, a county attorney, or the police.
Under current Liberian law, illegal abortion is punishable by up to five years in prison. Advocacy groups and feminists argued that misoprostol has served as a critical tool allowing women to bypass these legal and systemic barriers. They warn that for those who cannot afford the medication, the only remaining alternatives are often life-threatening.
Currently, the medication is sold in pharmacies and drugstores with minimal regulation. It is easily accessible to the public, with a single dose often costing as little as US$5 or more.
This announcement comes as the country monitors a high-stakes bill in the Liberian Senate. The new Public Health Law, passed by the House of Representatives in 2022, is currently being debated in a special Senate session where it faces a barrage of opposition. A key provision in the bill would legalize abortion up to 18 weeks of pregnancy, provided it is performed by a doctor. While the original version of the bill set the limit at 24 weeks, lawmakers later revised it to 18.
Misoprostol is an essential medicine recognized by the WHO for treating postpartum hemorrhage (PPH), managing miscarriages safely, and for use alongside other medicines in medical abortions. In Liberia, where the rate of teenage pregnancy remains high–with 1 in 3 girls between ages 15 and 19 being either a mother or pregnant–access to such medication is a critical health issue.
Liberia’s maternal mortality ratio stood at 628 per 100,000 live births in 2023. While this is a marked improvement from the 1,749 recorded in 2000, the rate still exceeds the regional average. The maternal mortality ratio is defined as the number of pregnancy-related deaths occurring during pregnancy or within 42 days of its end, per 100,000 live births.
“It saves lives. It prevents avoidable pain, infection, and death,” Solanke argues. “The burden of these restrictions most heavily impacts those already marginalized: low-income women, girls, rural communities, adolescents, survivors of sexual violence, and people living far from clinics.”
Misoprostol, the sale of which the Ministry of Health has restricted, sits at the center of one of global health’s most politically charged debates. It is the front line treatment for postpartum hemorrhage, the leading cause of maternal death in sub-Saharan Africa.
Amelia Siafa, acting executive director of the NGO SisterAid Liberia, viewed the statement as a move typical of governments worldwide seeking to reduce women’s autonomy. She raised a practical concern: “Does a young girl in Henry’s Town, Gbarpolu County, have access to a licensed pharmacist?”
The young feminist argued that many women, especially in rural communities, lack access to formal healthcare providers. “When policies focus only on restrictions without offering real alternatives, they do not solve the problem,” Siafa said. She added that when safe options are out of reach, women do not stop seeking care; they are instead pushed toward hidden, dangerous methods.
The Women NGOs Secretariat of Liberia (WONGOSOL) underscored that any regulatory measures must be implemented in a manner that does not unintentionally restrict access to life-saving services.
“At a time when Liberia continues to grapple with high maternal mortality, it is imperative that public health regulations strike a careful balance between control and access,” said Esther S. D. Eyeah David Yango, Executive Director of WONGOSOL. “Women and girls must not be pushed further into unsafe conditions due to barriers in accessing essential reproductive health services. Ensuring safe, regulated, and equitable access is both a public health priority and a human rights obligation.”
